| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.092 | 0.09 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.09 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |